European Commission logo
English English
CORDIS - EU research results
CORDIS

Hybrid drug-loaded plasmonic photothermal microneedle patch against skin infections

Project description

Microneedle for nosocomial skin infections

Drug-resistant bacteria cause nosocomial skin infections. New devices are necessary to facilitate local antibiotic delivery and improve drug efficiency. To provide proof-of-concept, the EU-funded HOTSKIN project will assess the technical and commercial feasibility of a device for nosocomial skin infection treatment. This hybrid microneedle patch penetrates difficult-to-infiltrate skin layers to deliver antibiotics and raise the local temperature to enhance drug effectiveness, obviating the need for high dosage systemic drug administration. The device can bolster the use of antibacterial drugs for the topical treatment of skin infections with improved dermatological delivery. HOTSKIN will validate the device’s fabrication process for additional commercial scalability and functionality with nanocarrier-drug complexes and also conduct extensive market analysis.

Objective

In this proof of concept project, we will assess the technical and commercial feasibility of a hybrid microneedle patch for the treatment of nosocomial skin infections caused by drug resistant bacteria. Not only does this device permeate difficult-to-penetrate skin layers to deliver antibiotics locally, it also weakens bacterial defences by raising local temperature to enhance drug effectiveness. In this manner, the need for high dosage systemic drug administration is avoided – reducing occurrence of associated side-effects and perpetuation of antimicrobial resistance. It holds the potential not only to revitalise antibacterials for topical, local treatment of skin infections, but to improve dermatological drug delivery as a platform device. In this project, we will validate the device’s fabrication process for additional commercial scalability and functionality with nanocarrier-drug complexes (for enhanced effectiveness of drug delivery to target site), develop a robust IP strategy and secure initial patents, and conduct extensive market analyses and competitor landscaping. Finally, we will formulate a strong business case, and depending on the results of these activities, establish a company.

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 100 000,00
Address
Nobels Vag 5
17177 Stockholm
Sweden

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)